The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease

International Journal of Cardiology

Volumn 142, Issue 1, 2010, Pages 107-109

  Celik, Turgay ^a   Iyisoy, Atila ^a   Yuksel, Cagdas ^b   Jata, Bekim ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Sarikamis Army District Hospital Turkey   (Turkey)

Author keywords

Angiotensin converting enzyme inhibitors; Asymmetric dimethylarginine

Indexed keywords

ANGIOTENSIN II; ARGININE; BISOPROLOL; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PERINDOPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCAVENGER; TEMOCAPRIL; THIOL GROUP; VON WILLEBRAND FACTOR; ZOFENOPRIL;

AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERTENSION; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHEAR STRESS; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 77953291482     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.109     Document Type: Article

References (12)

1. Kawata T., Daimon M., Hasegawa R., et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol (Dec 14 2007) [Electronic publication ahead of print]
2. Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134 10 Suppl (2004) 2842S-2847S
3. Szuba A., and Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor-evidence from epidemiological and prospective clinical trials. Pharmacol Rep 58 (2006) 16-20 Suppl
4. Rizzoni D., Muiesan M.L., Porteri E., et al. Effects of long-term therapy with lisinopril on resistance arteries of hypertensive patients with left ventricular hypertrophy. J Hypertens 15 (1997) 197-204
5. Ito A., Egashira K., Narishige T., Muramatsu K., and Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J. 65 (2001) 775-778
6. Kalinowski L., and Malinski T. Endothelial NADH/NADPH dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol 51 (2004) 459-469
7. Fu Y.F., Xiong Y., and Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol, 508 (2005) 167-175
8. Napoli C., Sica V., de Nigris F., Pignalosa O., Condorelli M., Ignarro L.J., et al. Sulfhydryl angiotensin converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 148 (2004) e5
9. Ito A., Egashira K., Narishige T., Muramatsu K., and Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J. 66 (2002) 811-815
10. Closs E.I., Basha F.Z., Habermeier A., and Förstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1 (1997) 65-73
11. Dierkes J., Westphal S., Martens-Lobenhoffer J., Luley C., and Bode-Böger S.M. Fenofibrate increases the l-arginine: ADMA ratio by increase of l-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 173 (2004) 239-244
12. Holven K.B., Haugstad T.S., Holm T., Aukrust P., Ose L., and Nenseter M.S. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr 89 (2003) 359-363